首页> 中国专利> 一种用于检测人间充质干细胞抑制Th17细胞增殖功能的试剂盒

一种用于检测人间充质干细胞抑制Th17细胞增殖功能的试剂盒

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明涉及一种用于检测人间充质干细胞抑制Th17细胞增殖功能的试剂盒。具体地，本发明提供一种MSC免疫调节功能检测试剂盒，所述试剂盒包括：小鼠抗人CD3单克隆抗体、rh IL‑1β、rh IL‑2、rh IL‑6、rh IL‑23、rh TGF‑β1、小鼠抗人(mouse anti human)IFN‑γ中和抗体、小鼠抗人IL‑4中和抗体、小鼠抗人CD3‑APC流式抗体、小鼠抗人CD4‑FITC流式抗体、小鼠抗人IL‑17A‑PE流式抗体。本发明试剂盒能能体外活化MSC，体外快速诱导Th17细胞，加入活化后的MSC共培养，可以用于人MSC细胞抑制免疫细胞增殖功能的检测。

著录项

公开/公告号CN112345747A

专利类型发明专利
公开/公告日2021-02-09

原文格式PDF
申请/专利权人上海赛比曼生物科技有限公司;无锡赛比曼生物科技有限公司;
展开▼

申请/专利号CN201910731332.X
发明设计人陈应炉;戴成祥;刘必佐;王静;李苏克;石颖轩;
展开▼

申请日2019-08-08
分类号G01N33/53(20060101);G01N33/531(20060101);G01N33/533(20060101);G01N33/543(20060101);G01N33/577(20060101);
代理机构31266 上海一平知识产权代理有限公司;
代理人胡丹;徐迅
地址 201210 上海市浦东新区中国(上海)自由贸易试验区法拉第路85号3号楼
入库时间 2023-06-19 09:51:02

法律信息

法律状态公告日

法律状态信息

法律状态
2023-09-08

专利申请权的转移 IPC(主分类):G01N33/53 专利申请号:201910731332X 登记生效日:20230822 变更事项:申请人变更前权利人:上海赛比曼生物科技有限公司变更后权利人:无锡赛比曼生物科技有限公司变更事项:地址变更前权利人:201210 上海市浦东新区中国(上海)自由贸易试验区法拉第路85号3号楼变更后权利人:214174 江苏省无锡市无锡惠山经济开发区惠山大道1699号七号楼一层A区、二层A区、二层B区变更事项:申请人变更前权利人:无锡赛比曼生物科技有限公司变更后权利人:

专利申请权、专利权的转移

相似文献

专利
中文文献
外文文献

1. 一种用于检测人间充质干细胞抑制Th17细胞增殖功能的试剂盒 [P] . 中国专利： CN112345747A . 2021-02-09
2. 一种用于检测人间充质干细胞抑制Th1细胞增殖功能的试剂盒 [P] . 中国专利： CN112345758A . 2021-02-09
3. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
4. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
5. use of a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lysosomal inhibitor, an golgi er protein transport inhibitor, an hsp90 chaperonin inhibitor, a heat shock response activator, a and a histone deacetylase inhibitor, use of 11-cis-retinal or 9-cis-retinal and a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lissosomal inhibitor, a er to golgi protein, a hsp90 chaperonin inhibitor, a heat shock response activator, a glycosidase inhibitor, and a histone deacetylase inhibitor, a method for increasing the amount of a biochemically functional conformation of a protein in a cell, composition pharmaceutical for the treatment of an ocular pcd, pharmaceutical composition for the treatment of retinitis pigmentosa, kit for the treatment of an ocular pcd, kit for the treatment retinitis pigmentosa, method for identifying a compound useful for the treatment of an individual having an ocular pcd, [P] . BRPI0615962A2 . 2011-05-31

机译：使用选自以下的化合物：蛋白酶体抑制剂，自噬抑制剂，溶酶体抑制剂，高尔基体蛋白转运抑制剂，hsp90伴侣蛋白抑制剂，热休克反应激活剂，α和组蛋白脱乙酰酶抑制剂，使用11 -顺式-视黄醛或9-顺式-视黄醛以及选自蛋白酶体抑制剂，自噬抑制剂，核糖体抑制剂，高尔基体蛋白er，hsp90伴侣蛋白抑制剂，热休克反应激活剂，糖苷酶的化合物抑制剂和组蛋白脱乙酰基酶抑制剂，一种增加细胞中蛋白质的生化功能构象量的方法，用于治疗眼pcd的组合物药物，用于治疗色素性视网膜炎的药物组合物，用于治疗视网膜色素变性的试剂盒眼用pcd，用于治疗色素性视网膜炎的试剂盒，用于鉴定可用于治疗具有眼用pcd的个体的化合物的方法，